Publications in collaboration with researchers from Hospital Clínico San Carlos de Madrid (27)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

2023

  1. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

    British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585

  4. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  5. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

2020

  1. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

    Thrombosis and Haemostasis, Vol. 120, Núm. 3, pp. 437-448

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Unraveling the effect of silent, intronic and missense mutations on VWF splicing: Contribution of next generation sequencing in the study of mRNA

    Haematologica, Vol. 104, Núm. 3, pp. 587-598

2018

  1. Role of multimeric analysis of von willebrand factor (VWF) in von willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

  2. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

    Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774

2016

  1. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

  2. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540

2015

  1. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial

    Clinical Infectious Diseases, Vol. 60, Núm. 3, pp. 405-414

2014

  1. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

    Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307

2010

  1. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation

    Annals of Oncology, Vol. 21, Núm. 9, pp. 1891-1897